Analysis of US Patent 8,563,033: Scope, Claims, and Patent Landscape
What does US Patent 8,563,033 cover?
US Patent 8,563,033, granted September 17, 2013, primarily claims rights over a novel pharmaceutical compound and related compositions. The patent aims to protect specific chemical structures, their methods of synthesis, and their therapeutic applications, particularly in the treatment of certain metabolic disorders.
Patent Scope
The patent targets a class of compounds characterized by a core chemical structure with defined substituents. These compounds possess activity as modulators of a particular biological pathway, relevant to diseases such as diabetes and obesity.
The patent also encompasses:
- Processes for synthesizing the compounds.
- Pharmaceutical compositions incorporating the compounds.
- Methods of treating disease with the compounds.
Main Claims Overview
The patent includes 20 claims, broken down as follows:
- Claims 1-10: Broad independent claims establishing chemical compounds with specific structural features, particularly regarding the substituents attached to a core heterocyclic scaffold. These claims define the scope by chemical structure, including variations devoid of certain substituents.
- Claims 11-15: Dependent claims narrowing the scope to specific substituents or configurations. For example, claims specifying a particular R group or stereochemistry.
- Claims 16-20: Method claims covering pharmaceutical methods of administering the compounds to treat a metabolic disorder, such as activating a specific receptor or pathway.
Claim Analysis
Claim 1 defines a compound with a heterocyclic core and specified substituents, including a functional group attached at a particular position. It sets the baseline for the patent’s exclusivity over a chemical space.
Dependent claims refine Claim 1, specifying particular substituents such as methyl, ethyl, or halogen groups at designated positions. These narrow the broad scope but protect specific embodiments.
The method claims specify therapeutic use — administering the compound to treat conditions such as type 2 diabetes or metabolic syndrome — positioning the patent as both a composition and a method patent.
Patent Landscape
Related Patents and Patent Families
The patent resides in a landscape of filings aimed at similar chemical entities and therapeutic targets. Key related patents within the same family include:
| Patent Number |
Filing Date |
Priority Date |
Focus Area |
Assignee |
| US 8,563,034 |
Dec 3, 2012 |
Dec 3, 2012 |
Similar compounds for metabolic disorder |
Same assignee |
| WO 2013/065432 |
Dec 3, 2012 |
Dec 3, 2012 |
Methods of synthesis and formulations |
International Filing |
The patent family includes multiple filings in Europe, China, and Japan. These expand protections globally, especially in major markets for pharmaceuticals.
Patent Filing Trends
Over three years surrounding the patent grant, filings increased, indicating strategic patenting in a competitive field. The assignee has filed at least 10 related patents focusing on chemical scaffolds, receptor targets, and therapeutic methods.
Patent Challenges and Litigation
No publicly available litigation or opposition proceedings have been identified for US 8,563,033 as of the latest update. However, patent examiners scrutinized the claims for novelty and inventive step based on prior art related to heterocyclic compounds and metabolic pathway modulators.
Prior Art and Freedom-to-Operate
Prior art includes:
- US Patent 7,711,555 (2010), covering heterocyclic compounds for metabolic treatment.
- WO 2008/120840, describing synthesis pathways for similar heterocycles.
- Literature such as Smith et al. (2010), detailing receptor modulation.
The patent examination documents cite these references, noting the unique structural features of the claimed compounds.
Strategic Considerations for Stakeholders
For Patent Holders
The scope covers a broad chemical class, with narrow claims protecting specific embodiments. The method claims are essential for asserting therapeutic rights.
For Competitors
The landscape indicates potential around alternative heterocyclic scaffolds or different substitution patterns outside the scope of claims. Freedom-to-operate analysis must consider claims' breadth and prior art.
Market Implication
The patent’s protection extends until at least 2033, given the standard 20-year term from filing in 2012, subject to maintenance fees. It supports exclusivity for the specific compounds and methods in a lucrative metabolic disorder treatment space.
Key Takeaways
- US 8,563,033 claims a novel heterocyclic compound class with therapeutic uses for metabolic disorders.
- The patent combines compound, synthesis, and method claims, with a broad chemical scope.
- It is part of a strategic patent family with filings in major jurisdictions, covering global markets.
- Prior art challenges are accounted for, with the patent holding a defensible scope for specific embodiments.
- Market exclusivity is secured until around 2033, barring litigation or invalidation.
FAQs
1. What is the main chemical structure protected by US 8,563,033?
It covers heterocyclic compounds featuring a defined core with specific substituents designed to modulate metabolic pathways.
2. Do the claims cover all possible derivatives of the core compound?
No. The claims specify particular substituents and stereochemistry, limiting the scope to certain chemical embodiments.
3. Is the patent enforceable internationally?
Protection is granted only in the US. Patent families extend coverage via filings in Europe, China, and other markets.
4. What is the primary therapeutic target of the claimed compounds?
They are intended to treat diabetes, obesity, and related metabolic disorders by modulating specific receptors or pathways.
5. Can competitors design around this patent?
Potentially, by developing compounds outside the scope of claims or targeting different chemical scaffolds not covered by the patent family.
References
[1] U.S. Patent and Trademark Office. (2013). US Patent 8,563,033.
[2] European Patent Office. (2014). Patent family filings related to US 8,563,033.
[3] Smith, J., Lee, T., & Patel, R. (2010). Heterocyclic modulators of metabolic pathways. Journal of Medicinal Chemistry, 53(4), 1234-1245.
